Nuro's latest partnership in Houston is allowing prescription and essentials to be delivered to Houstonians across three ZIP codes. Photo courtesy of Nuro

The latest partnership from California-based Nuro, which has a fleet of driverless vehicles in Houston, means prescription drug delivery to certain parts of Houston.

Rhode Island-based CVS Pharmacy will offer the delivery option for prescriptions and essentials for free beginning in June for three ZIP codes near a CVS location in Bellaire (5430 Bissonnet St., Bellaire, TX 77401).

"We are seeing an increased demand for prescription delivery," says Ryan Rumbarger, senior vice president of store operations at CVS Health, in a release. "We want to give our customers more choice in how they can quickly access the medications they need when it's not convenient for them to visit one of our pharmacy locations."

The driverless delivery option will be made available through the CVS app, and recipients will have to prove their identity to retrieve their order.

Nuro has been expanding throughout the Houston market for over a year now — first entering the Houston market with its Kroger pilot program, but this partnership represents a whole new sector for the robotics company.

"Today, we are excited to expand into an entirely new vertical: health," says Dave Ferguson, Nuro's co-founder and president, in the release. "Through our partnership with CVS, we hope to make it easier for customers to get medicine, prescriptions, and the other things they need delivered directly to their homes."

Following Nuro's initial deal with Kroger, the company expanded to pizza delivery with Domino's Pizza before forming agreement with Walmart. Earlier this year, the company received approval from the United States Department of Transportation's National Highway Traffic Safety Administration that allowed Nuro's vehicles on public roads without the features of traditional, passenger-carrying vehicles — like side mirrors or windshields, for instance.

In January, InnovationMap spoke with Sola Lawal, Nuro product operations manager in Houston, and asked him about what types of partnerships Nuro is targeting.

"The way that we think about this is that this new technology and our mission of accelerating robotics for everyday life, is we will bring the people what they want," Lawal told InnovationMap.

And as far as continuing to expand in Houston, the city's diversity, varied roadscapes, and regulatory support makes it prime for robotics and self-driving technology.

"Houston is our first full-scale operations city," said Lawal. "All eyes at Nuro are focused on Houston."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.